Asensus

As of February 23, 2021, TransEnterix has been renamed Asensus Surgical, Inc.

Along with the name change, the ticker symbol will change to “ASXC” upon the open of trading on Friday, March 5, 2021. Up until that point, the stock will continue to trade under the company name TransEnterix and ticker symbol TRXC.

If you are an existing investor, your ownership will not be impacted. Beginning on March 5, 2021, your holdings will automatically be renamed as Asensus Surgical, ticker symbol ASXC. Up until that point, the stock will continue to show up as TransEnterix and ticker symbol TRXC.

 

transe20210222_8k.htm
false 0000876378 0000876378 2021-02-23 2021-02-23


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
 
FORM 8-K
_________________
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
February 23, 2021
Date of Report (date of earliest event reported)
_________________
 
TransEnterix, Inc.
(Exact name of Registrant as specified in its charter)
_________________
 
Delaware
(State or other jurisdiction of incorporation or organization)
 
0-19437
(Commission
File Number)
 
11-2962080
(I.R.S. Employer
Identification Number)
 
635 Davis Drive, Suite 300
Morrisville, North Carolina 27560

(Address of principal executive offices)
 
919-765-8400
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
_________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock
$0.001 par value per share
 
TRXC
 
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐
 


 
 

 
Item 7.01 Regulation FD Disclosure
 
On February 23, 2021, TransEnterix, Inc., a Delaware corporation (the “Company”) is holding an Investor Day conference. Among the topics to be discussed, the Company announced its corporate name change to Asensus Surgical, Inc. The Investor Day presentation is furnished herewith as Exhibit 99.1.
 
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 8.01 Other Events
 
On February 23, 2021, the Company also issued a press release announcing its name change, effective February 23, 2021, and a change of its trading symbol to ASXC, to be effective on March 5, 2021. The press release is filed herewith as Exhibit 99.2.
 
Item 9.01 Financial Statements and Exhibits
 
(d) Exhibits.
 
99.1
 
99.2
 
104
 
Cover Page Interactive Data File (formatted in inline XBRL)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
TRANSENTERIX, INC.
Date: February 23, 2021
By:
/s/ Shameze Rampertab
Shameze Rampertab
Executive Vice President and Chief Financial Officer
 
 
 
Image Exhibit

Exhibit 99.1

 

 

 

https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide01.jpg

 

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide02.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide03.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide04.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide05.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide06.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide07.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide08.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide09.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide10.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide11.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide12.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide13.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide14.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide15.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide16.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide17.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide18.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide19.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide20.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide21.jpg

 

 

 
https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-slide22.jpg

 

 
ex_228359.htm

 

Exhibit 99.2

 

https://cdn.kscope.io/6108ec7b770c5a00e6b5ff9b2a8749b2-tr01.jpg

FOR IMMEDIATE RELEASE

 

TransEnterix Announces Name Change to Asensus Surgical and Introduces a New Category of Surgery, Performance-Guided Surgery

 

New name reflects commitment to pioneering a new era of Performance-Guided Surgery to help improve surgical results and patient outcomes

 

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--February 23, 2021-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc. The name change reflects the company's broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. While the company name change is effective today, the company's stock will begin trading under the new ticker symbol, NYSE American: ASXC, and name, Asensus Surgical, Inc., at the open of trading on March 5, 2021.

 

Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). Today, the Senhance Surgical System is being used by over 100 active surgeon users across three continents with over 4,000 procedures performed across a wide variety of surgical specialties.

 

“As we work to create the future of surgery we need to enable surgeons to take the best surgical practices and techniques from everywhere and enable them to be leveraged anywhere; this is what digital technology has enabled us to do,” said Anthony Fernando, President and Chief Executive Officer of Asensus. “As the company evolves from a robotics company to a digital surgery company, the rebrand better reflects our vision and we know that Asensus has the technology, the team, and the opportunity to create a new paradigm in best surgical practices and techniques we call performance-guided surgery.”

 

Sensus is Latin for “cognition,” making the connection between surgeons’ knowledge and the augmented intelligence technology to perceive and develop future innovations. The inclusion of the “A” in front of “sensus” lends itself to the idea of augmented intelligence and being at the forefront of innovation. Asensus also speaks to “ascending” and “elevating,” which speaks to the company’s mission to elevate robotic surgery: to drive predictable outcomes, to optimize resources and costs, and to work with hospital systems that seek to strive to employ innovative healthcare strategies.

 

 

 

As part of the name change, Asensus Surgical also released a new company logo and rebranded the company website at www.Asensus.com.

 

About Asensus Surgical, Inc.

 

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.Senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.transenterix.com/indications-for-use/.

 

Forward-Looking Statements

 

This press release includes statements relating to our vision for the future of performance-guided surgery and the role the Senhance Surgical System may play. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, and include whether we will be well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals and patients globally. For a discussion of the risks and uncertainties associated with our business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

INVESTOR CONTACT:

 

Mark Klausner or Mike Vallie, +1 443-213-0499

 

invest@transenterix.com

 

Or

 

MEDIA CONTACT

 

Kristin Schaeffer

 

CG Life

 

858-354-8850

 

kschaeffer@cglife.com